injection Sekucinumab

PreclinicalMonoclonal antibody

JJinnah Postgraduate Medical Centre

injection Sekucinumab is one of 29 biologic programs targeting Psoriasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

PsoriasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Preclinical

37 2

Cosentyx

Novartis

Preclinical

53 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis1 trial

Efficacy of Injection Sekucinumab in Erythrodermic Psoriasis

Not yet recruiting·JJinnah Postgraduate Medical Centre··NCT06801028·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for injection Sekucinumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — injection Sekucinumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for injection Sekucinumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinnah Postgraduate Medical Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: JJinnah Postgraduate Medical Centre

injection Sekucinumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News